Novo Nordisk shares technical analysis: Consolidation near $38.82 support as weak momentum persists

Novo Nordisk shares technical analysis: Consolidation near $38.82 support as weak momentum persists
Novo Nordisk steady at $40.3 today

Novo Nordisk A/S (NVO) stock is trading at $40.3, showing no change on the day after an intraday gap down. The price remains below its key moving averages, signaling persistent seller control across timeframes.

NVO price prediction
24H 1.52%
$40.69
48H 1.97%
$40.87
7D 1.55%
$40.7
1M 6.26%
$42.59
3M 13.27%
$45.4
6M -21.11%
$31.62
12M -19.11%
$32.42
Current price: $40.08 -0.6200 1.52%
Real-time Data 10:10
Daily range 40.23 Arrow from to Icon 40.96
Weekly range 40.10 Arrow from to Icon 42.01
Loading...

Highlights

  • Novo Nordisk raised its 2026 sales and profit forecast following a 4% increase in third-quarter adjusted sales to DKK 79.2 billion.
  • Wegovy obesity treatment surpassed five million prescriptions since launch, supporting continued market share expansion in key growth areas.
  • Shares of Novo Nordisk trade below major moving averages and bearish momentum prevails, with the price expected to remain between $38.82 and $41.78.

Upgraded outlook as Wegovy-fueled sales drive business momentum

Novo Nordisk raised its 2026 sales and profit outlook following a 4% increase in third-quarter adjusted sales to DKK 79.2 billion, driven by continued strong demand for its obesity treatments and expanding use of the Wegovy pill, according to MarketBeat. The company’s revised guidance reflects concrete momentum from recent commercial performance, with realized growth in core business lines supporting future forecasts. Additionally, Wegovy prescriptions have surpassed five million since launch, showing robust uptake and contributing to Novo Nordisk's expanding market presence, Yahoo Finance reported.

Novo Nordisk A/S asset chart
Novo Nordisk A/S price dynamics. Source: TradingView.

Bearish momentum dominates as resistance levels cap upside

NVO remains below the MA-20 and MA-50 on the hourly chart, as well as the MA-200 on the daily, highlighting defined resistance overhead. The Ichimoku Kijun level at $41.39 forms immediate resistance, while support is clearly marked at $38.82. MACD and ADX both signal active sell conditions, indicating prevailing bearish momentum. Meanwhile, RSI, Stoch RSI, and CCI are all neutral in their respective ranges, and neither Bull/Bear Power nor Awesome Oscillator provide definitive directional cues, with Bull/Bear Power slightly negative and AO neutral.

Downtrend risk prevails as rangebound trade expected short term

In the short term, NVO is expected to trade within a volatility band between $38.82 and $41.78. There is a 70% probability of a downward move, with the baseline scenario anticipating the price to remain rangebound. A sustained break above the $41.39 resistance could trigger an advance toward higher levels, while a move below $38.82 would likely accelerate further declines.

Viktoras Karapetjanc, expert at Traders Union, sees Novo Nordisk’s outlook upgrade as a reflection of genuine momentum in its core obesity segment. He notes robust fundamental drivers supporting the firm, particularly with prescription strength in Wegovy and sustained commercial execution. However, he acknowledges the current technical backdrop is pressured and keeps the stock in a defined short-term range. 'While bears control the short-term trend, Novo Nordisk’s strong business fundamentals keep me constructive for a future breakout above $41.39 if resistance is cleared.'

Previously it was reported that Novo Nordisk’s robust earnings and raised outlook were tempered by ongoing technical resistance and persistent selling pressure. The current analysis reinforces this view, highlighting continued seller dominance and pointing to $38.82 as a critical support level for traders to monitor for signs of further downside risk.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.